Health Trials

About this trial

This research is being done to determine if the administration of a short course of intravenous hydrocortisone, an anti-inflammatory medication, to patients with severe acute pancreatitis will improve their clinical outcomes and decrease the length of hospitalization. We think that because inflammation in the body drives the progression of pancreatitis, giving a short course of intravenous hydrocortisone may mitigate disease progression and improve clinical outcomes in patients with severe acute pancreatitis.

Eligibility criteria

Qualifiers

Adult (≥18 years)

Acute pancreatitis as defined by a clinical diagnosis of pancreatitis and a lipase level ≥3x the upper limit of normal.

Admission or planned admission to an intensive care unit

SOFA disease severity score ≥3 (or at least 3 points above a known baseline)

Disqualifiers

Known diagnosis of autoimmune pancreatitis

Existing clinical indication for corticosteroids at a dose >5mg of oral prednisone daily (or equivalent)

Contraindication to receiving corticosteroids

Protected populations (prisoners)

Trial design

Treatments tested in this trial

  • Hydrocortisone
  • Placebo

Treatment groups

86 Participants
are divided into 2 treatment groups

Locations

1
Beth Israel Deaconess Medical Center02215, BostonMassachusetts, United States

Sponsors and collaborators

Beth Israel Deaconess Medical Center

Lead sponsor

Source ClinicalTrials.gov